| Investor | Blue Owl Capital Holdings LP |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Blue Owl Capital Holdings LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | 13G | AKTS / Aktis Oncology, Inc. | 3,161,348 | |||||
| 2026-05-14 | 13G/A | RPTX / Repare Therapeutics Inc. | 3,372,499 | 0 | ||||
| 2026-05-14 | 13G/A | LRMR / Larimar Therapeutics, Inc. | 8,464,663 | 10,739,492 | ||||
| 2026-05-14 | 13G/A | CNTX / Context Therapeutics Inc. | 6,357,928 | 5,089,015 | ||||
| 2026-05-14 | 13G/A | IMA / ImageneBio, Inc. | 823,785 | 959,337 | ||||
| 2026-02-12 | 13G/A | LRMR / Larimar Therapeutics, Inc. | 4,166,829 | 8,464,663 | ||||
| 2026-02-12 | 13G | FOA / Finance of America Companies Inc. | 827,409 | |||||
| 2026-02-12 | 13G/A | 0 | ||||||
| 2026-02-12 | 13G/A | NCDL / Nuveen Churchill Direct Lending Corp. | 3,091,553 | 2,143,626 | ||||
| 2026-02-12 | 13G | IMA / ImageneBio, Inc. | 540,924 | 823,785 | ||||
| 2026-02-12 | 13G | BMEA / Biomea Fusion, Inc. | 2,500,000 | 4,451,219 | ||||
| 2025-11-14 | 13G/A | IMA / ImageneBio, Inc. | 540,924 | |||||
| 2025-11-14 | 13G/A | BMEA / Biomea Fusion, Inc. | 3,800,000 | 2,500,000 | ||||
| 2025-11-14 | 13G/A | NCDL / Nuveen Churchill Direct Lending Corp. | 4,039,552 | 3,091,553 | ||||
| 2025-11-05 | 13D/A | KPLT / Katapult Holdings, Inc. | 4,306,771 | 21,421 | ||||
| 2025-10-29 | 13D/A | KPLT / Katapult Holdings, Inc. | 3,952,776 | 4,306,771 | ||||
| 2025-10-23 | 13D/A | KPLT / Katapult Holdings, Inc. | 3,407,261 | 3,952,776 | ||||
| 2025-10-20 | 13D/A | KPLT / Katapult Holdings, Inc. | 2,867,316 | 3,407,261 | ||||
| 2025-10-14 | 13D/A | KPLT / Katapult Holdings, Inc. | 2,603,447 | 2,867,316 | ||||
| 2025-10-06 | 13D | KPLT / Katapult Holdings, Inc. | 667,685 | 2,603,447 | ||||
| 2025-09-05 | 13G | KPLT / Katapult Holdings, Inc. | 667,685 | |||||
| 2025-08-11 | 13G | BMEA / Biomea Fusion, Inc. | 3,800,000 | |||||
| 2025-05-15 | 13G/A | MRKR / Marker Therapeutics, Inc. | 554,250 | 1,127,052 | ||||
| 2025-02-14 | 13G | ABR.PRE / Arbor Realty Trust, Inc. - Preferred Stock | 360,000 | |||||
| 2025-02-14 | 13G | 50,000 | ||||||
| 2025-02-14 | 13G | LFT.PRA / Lument Finance Trust, Inc. - Preferred Stock | 200,000 | |||||
| 2025-02-14 | 13G/A | GAQ / Generation Asia I Acquisition Limited | 573,000 | 0 | ||||
| 2025-02-14 | 13G | MRKR / Marker Therapeutics, Inc. | 554,250 | |||||
| 2025-02-14 | 13G/A | TRML / Tourmaline Bio, Inc. | 1,530,401 | 1,079,321 | ||||
| 2025-02-14 | 13G/A | AEON / AEON Biopharma, Inc. | 3,341,204 | 3,049,361 | ||||
| 2025-02-14 | 13G/A | CNTX / Context Therapeutics Inc. | 5,411,290 | 6,357,928 | ||||
| 2025-02-14 | 13G/A | SGMT / Sagimet Biosciences Inc. | 1,673,877 | 1,323,877 | ||||
| 2024-11-14 | 13G | AEON / AEON Biopharma, Inc. | 3,341,204 | |||||
| 2024-11-14 | 13G | CNTX / Context Therapeutics Inc. | 5,411,290 | |||||
| 2024-11-14 | 13G | AAGR / African Agriculture Holdings Inc. | 3,119,625 | |||||
| 2024-11-14 | 13G | GAQ / Generation Asia I Acquisition Limited | 573,000 | |||||
| 2024-11-14 | 13G | IKNA / Ikena Oncology, Inc. | 4,091,118 | |||||
| 2024-11-14 | 13G | NCDL / Nuveen Churchill Direct Lending Corp. | 4,039,552 | |||||
| 2024-11-14 | 13G | SGMT / Sagimet Biosciences Inc. | 1,673,877 | |||||
| 2024-11-14 | 13G/A | RPTX / Repare Therapeutics Inc. | 3,122,499 | 3,372,499 | ||||
| 2024-11-14 | 13G/A | LRMR / Larimar Therapeutics, Inc. | 3,414,468 | 4,166,829 | ||||
| 2024-11-14 | 13G/A | TRML / Tourmaline Bio, Inc. | 1,332,302 | 1,530,401 | ||||
| 2024-11-14 | 13G/A | ENGN / enGene Therapeutics Inc. | 1,234,760 | 3,095,069 | ||||
| 2024-11-14 | 13G/A | CGEM / Cullinan Therapeutics, Inc. | 3,419,842 | 2,010,972 | ||||
| 2024-11-14 | 13G/A | ORTX / Orchard Therapeutics plc - Depositary Receipt (Common Stock) | 15,596,600 | 0 | ||||
| 2024-11-14 | 13G/A | PLRX / Pliant Therapeutics, Inc. | 3,004,199 | 3,004,199 | ||||
| 2024-11-14 | 13G/A | SYRS / Syros Pharmaceuticals, Inc. | 1,493,252 | 515,855 | ||||
| 2024-02-14 | 13G | ENGN / enGene Therapeutics Inc. | 1,234,760 | |||||
| 2024-02-14 | 13G | ORTX / Orchard Therapeutics plc - Depositary Receipt (Common Stock) | 15,596,600 | |||||
| 2024-02-14 | 13G | RPTX / Repare Therapeutics Inc. | 3,122,499 | |||||
| 2024-02-14 | 13G | CGEM / Cullinan Therapeutics, Inc. | 3,419,842 | |||||
| 2024-02-14 | 13G | LRMR / Larimar Therapeutics, Inc. | 3,414,468 | |||||
| 2024-02-14 | 13G | SYRS / Syros Pharmaceuticals, Inc. | 1,493,252 | |||||
| 2024-02-14 | 13G | PLRX / Pliant Therapeutics, Inc. | 3,004,199 | |||||
| 2024-02-14 | 13G | TRML / Tourmaline Bio, Inc. | 1,332,302 |
